COLORADO SPRINGS, Colo., March 3 /PRNewswire/ -- The latest product from HemoGenix propels hemotoxicity testing into the 21st century. For years, non-predictive, conventional hemotoxicity testing late in drug development as part of pre-clinical studies has been the norm. HemoGenix has now further developed its HALO Platform to test and predict the effects of virtually any compound on the lympho-hematopoietic system during the earliest phases of drug development. This unique hemotoxicity testing system is based on the multifunctional ability of HALO to simultaneously detect and measure the effects of compounds on 7 different lympho-hematopoietic populations using primary human bone marrow as the target tissue. By testing compounds on 7 different populations, including primitive and mature stem cells, 3 hematopoietic and 2 lymphopoietic progenitor cell populations, the effects of the compound both in the hematopoietic organs and circulation can be predicted for the whole system. The ability to use primary human bone marrow so early in drug development allows IC values (IC50, IC75, and IC90 values) to be determined from which estimations of the initial or clinically relevant starting doses can be predicted.
HemoGenix Inc. in conjunction with Biotrin International has also recently made available a flow cytometric assay for detecting and quantifying oxidative DNA damage to lympho-hematopoietic cells. OxyFLOW(TM) is an assay platform that detects oxidative DNA damage as a result of stress, xenobiotics and the administration of drugs. Reactive oxygen species (ROS) produced under these conditions are particularly damaging to DNA. The result of oxidative DNA damage is the formation of 8-oxoguanine adducts.
HemoGenix(TM), a contract research and development company, is the leader in stem cell hemotoxicology, specializing in testing new drug candidates that are in the process of being developed by biotechnology and pharmaceutical companies for their toxic side effects on stem cells and other proliferating cells of the blood-forming system. HemoGenix(TM) focuses on non-invasive, physiological, in vitro, cell-based screening and monitoring assays to help detect, quantify and predict the effect of compounds on the blood-forming system. To do this effectively and rapidly, HemoGenix(TM) developed the HALOTM (Hematopoietic/Hemotoxicity Assays via Luminescence Output) Platform.
HemoGenix(TM) can draw on over 200 tests and procedures in its armory to help drug development companies detect and analyze potential toxic side effects. The company also develops its own new tests to provide the biotechnology and pharmaceutical community with new and improved tools to detect hemotoxicity. HemoGenix(TM) is the only company in the world that has made this its single specialty.
More information is available at http://www.hemogenix.com/ and http://www.biotrin.com/.
George L. Down
CONTACT: George L. Down of HemoGenix Inc., +1-719-264-6250,firstname.lastname@example.org